Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/26/2870466/0/en/Biodexa-Enters-Into-Exclusive-License-to-eRapa-a-Phase-3-Ready-Asset-for-the-Treatment-of-Familial-Adenomatous-Polyposis-FAP.html
https://www.globenewswire.com/news-release/2024/04/19/2866120/0/en/Preliminary-Results-for-the-Year-Ended-31-December-2023.html
https://www.globenewswire.com//news-release/2024/02/23/2834442/0/en/Biodexa-Announces-Positive-Top-Line-Phase-I-Clinical-Trial-Results-for-Diffuse-Midline-Glioma-and-Provides-R-D-Update.html
https://www.globenewswire.com//news-release/2024/02/08/2826009/0/en/Biodexa-Reports-12-Month-Survival-in-MAGIC-G1-Study-of-MTX110-in-Recurrent-Glioblastoma-Patients.html
https://www.globenewswire.com//news-release/2024/02/07/2825207/0/en/Biodexa-Announces-Allowance-of-U-S-Patent-Covering-Tolimidone.html
https://www.globenewswire.com//news-release/2024/01/22/2813041/0/en/Biodexa-CEO-Issues-Shareholder-Letter-Highlighting-Progress-in-2023-and-Expected-Milestones-in-2024.html
https://www.globenewswire.com/news-release/2023/12/29/2801964/0/en/Biodexa-Appoints-Ann-Merchant-to-the-Board-of-Directors.html
https://www.globenewswire.com//news-release/2023/12/21/2800326/0/en/Biodexa-Announces-Closing-Of-6-0-Million-Underwritten-Public-Offering-Including-Full-Exercise-Of-Overallotment-Option.html
https://www.globenewswire.com//news-release/2023/12/19/2798550/0/en/Biodexa-Announces-Pricing-of-5-2-Million-Underwritten-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/27/2786218/0/en/Biodexa-Enters-Into-Agreements-to-Acquire-Exclusive-Worldwide-License-to-Tolimidone-a-Phase-II-Ready-Asset-for-Type-1-Diabetes.html